Projected lives saved and economic value of mRNA cancer immunotherapies in the United States
Authors:
- Chad R. WellsCWChad R. Wells
- Abhishek PandeyAPAbhishek Pandey
- Carolyn BawdenCBCarolyn Bawden
- Yang YeYYYang Ye
- Bilori BiloriBBBilori Bilori
- Lilia Potter-SchwartzLPLilia Potter-Schwartz
- Lamia AyazLALamia Ayaz
- Seyed M. MoghadasSMSeyed M. Moghadas
- Jeffrey P. TownsendJTJeffrey P. Townsend
- Meagan C. FitzpatrickMFMeagan C. Fitzpatrick
- Alison P. GalvaniAGAlison P. Galvani
Open Access
- 8 August 2026
- journal article
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 62
Abstract
No abstract availableFunding Information
- Natural Sciences and Engineering Research Council of Canada
This publication has 19 references indexed in Scilit:
- Personalised cancer vaccines and new regulatory strugglesThe Lancet Oncology, 2025
- RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancerNature, 2025
- Neoantigen-specific mRNA/DC vaccines for effective anticancer immunotherapyGenes & Immunity, 2024
- Quality by design for mRNA platform purification based on continuous oligo-dT chromatographyMolecular Therapy Nucleic Acids, 2024
- Cancer mRNA vaccines: clinical advances and future opportunitiesNature Reviews Clinical Oncology, 2024
- Individualised neoantigen cancer vaccine therapyThe Lancet, 2024
- Return on Investment of the COVID-19 Vaccination Campaign in New York CityJAMA Network Open, 2022
- mRNA as a Transformative Technology for Vaccine Development to Control Infectious DiseasesMolecular Therapy, 2019
- mRNA-based therapeutics — developing a new class of drugsNature Reviews Drug Discovery, 2014
- Dendritic-Cell-Based Therapeutic Cancer VaccinesImmunity, 2013